Drug
Lebrikizumab
Lebrikizumab: highest development phase Post-Market, developed by Almirall, Roche. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall, Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| lebrikizumab NCT06906497 | Post-Market | Atopic Dermatitis |
| Lebrikizumab NCT05916365 | Phase 3 | Atopic Dermatitis |
| Lebrikizumab NCT05990725 | Phase 3 | Atopic Dermatitis |
| Lebrikizumab NCT06526182 | Phase 3 | Dermatitis, Atopic |
| Lebrikizumab NCT07873801 | Phase 3 | Atopic Dermatitis |
| Lebrikizumab NCT07542483 | Phase 3 | Nummular Eczema |
| Lebrikizumab NCT05149313 | Phase 3 | Dermatitis, Atopic |
| Lebrikizumab NCT01987492 | Phase 2 | Asthma |
Latest
No recent events.
Follow Lebrikizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.